The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

July 1, 2013 • By Stephanie Cajigal

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
  • 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
Explore This Issue
July 2013
Also By This Author
  • California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
Aim for RA Remission

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

SANTA MONICA, CALIF.—The current state of rheumatoid arthritis (RA) treatment should include early diagnosis with an ultimate goal of remission, RA expert Paul Emery, MA, MD, said here on May 18 at the California Rheumatology Alliance 9th Annual Medical and Scientific Meeting.

Dr. Emery, professor of rheumatology and head of the academic unit of musculoskeletal disease at the University of Leeds in Leeds, U.K., opened his presentation by emphasizing the importance of early referral recommendations as a means of intervention.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Leeds, for example, patients are referred by primary care physicians on the basis of new onset arthritis (nontraumatic) or symptoms of inflammation, including early morning stiffness or swelling or responses to nonsteroidal antiinflammatory drugs (NSAIDs). In fact, primary care providers are asked to refer patients on the basis of history rather than having them wait for test results.

“If they’d like to do the test, great, but don’t do the test and wait for the referral,” Dr. Emery said.

He noted that test results at this stage are likely to be negative. “Nearly the vast majority of patients will not have erosions,” he said. “CRP [C-reactive protein] won’t be raised in most of them, and only about 40% at this stage will have an autoantibody. As we begin to believe that the period of time before you start therapy is absolutely critical, then that’s not the way to handle patients, so primary care refers on the basis of history.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

If primary care physicians will not refer, Dr. Emery said he asks that they test for anticitrullinated protein antibodies (ACPA) and erythrocyte sedimentation rate (ESR) or plasma viscosity (PV), the latter two of which, he says, are more sensitive than a CRP test at onset. “You’ll find more patients who have raised ESR who have early onset,” he said.

Role of Guidelines

Dr. Emery also reviewed the impact of the ACR/ EULAR criteria for the classification of rheumatoid arthritis, pointing out there’s been a debate among rheumatologists about what RA actually is.

The 2010 criteria define RA as persistent small-joint arthritis, inflammatory arthritis requiring treatment with methotrexate (MTX), persistent synovitis with capacity to cause erosions as detected with an ultrasound, or intraarticular synovitis with erosions or precursors of erosions, such as osteitis, as seen on MRI.1

“The EULAR/ACR initiative was set up to have earlier identification of RA on the basis of a lot of data showing that early therapy was better and to differentiate from significant other pathology,” he said. “It used the requirement for MTX as a surrogate for diagnosis. Some people were very unhappy with that, but I think the new criteria have shown to be a valuable asset.”

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: RA, Remission, Rheumatoid arthritis, TreatmentIssue: July 2013

You Might Also Like:
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
  • 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)